A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

References

• CoiffierBHaiounCKettererNRituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyBlood199892192719329731049
   PubMed Web of Science ®Google Scholar
• DelarueRHaiounCRibragVGroupe d’Etude des Lymphomes de l’Adulte (GELA)CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’AdulteBlood20131211485322718839
   PubMed Web of Science ®Google Scholar
• ForstpointnerRDreylingMReppRGerman Low-Grade Lymphoma Study GroupThe addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2015104103064307215284112
   PubMedGoogle Scholar
• van OersMHKlasaRMarcusRERituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBaseline20061081032953301
   Google Scholar
• VoseJMLinkBKGrossbardMLCzuczmanMGrillo-LopezAFisherRILong-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphomaLeuk Lymphoma200546111569157316236611
   PubMed Web of Science ®Google Scholar
• ByrdJCJonesJJWoyachJAJohnsonAJFlynnJMEntering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinicianJ Clin Oncol201432273039304725049322
   PubMed Web of Science ®Google Scholar
• European Hematology Association19th Congress of the European Hematology Association, Milan, Italy, June 12–15, 2014Haematologica2014991 suppl249
   Google Scholar
• PazdurRNew Drug Application Approval – Imbruvica (Department of Health and Human Services Food and Drug Admistration) Ref ID 33957882013
   Google Scholar
• PanZScheerensHLiS-JDiscovery of selective irreversible inhibitors for Bruton’s tyrosine kinaseChem Med Chem200721586117154430
   PubMedGoogle Scholar
• MohamedAYuLBackesjoCVargasLBergloASmithCIEBruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domainImmunol Rev2009228587319290921
   PubMed Web of Science ®Google Scholar
• BuggyJJBruton tyrosine kinase (BTK) and its role in B-cell malignancyInt Rev Immunol201232211913222449073
   PubMedGoogle Scholar
• CinarMHamedaniFMoZCinarBAminHMAlkanSBruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosisLeuk Res201337101271127723962569
   PubMed Web of Science ®Google Scholar
• DavisRENgoVNLenzGChronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature20104637277889220054396
   PubMed Web of Science ®Google Scholar
• BrutonOAgammaglobulinemiaPediatrics1952972272814929630
   PubMed Web of Science ®Google Scholar
• TsukadaSRawlingsDJWitteONRole of Bruton’s tyrosine kinase in immunodeficiencyCurr Opin Immunol199466236307946052
   PubMed Web of Science ®Google Scholar
• SatterthwaiteABWitteONWitteOThe role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspectiveImmunol Rev2000612012710933597
   PubMedGoogle Scholar
• MaasAHendriksRWRole of Bruton’s tyrosine kinase in B cell developmentDev Immunol2001817118111785667
   PubMedGoogle Scholar
• PonaderSBurgerJABruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignanciesJ Clin Oncol201432171830183924778403
   PubMed Web of Science ®Google Scholar
• Indications and usage Imbruvica is indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is based on overall response rate. An improvement in survival or disease-related s; 2013
   Google Scholar
• HonigbergLASmithAMSirisawadMThe Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProc Natl Acad Sci U S A201010729130751308020615965
   PubMed Web of Science ®Google Scholar
• HutchinsonCVDyerMJSBreaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemiaBr J Haematol2014166122224749490
   PubMed Web of Science ®Google Scholar
• BurgerJABuggyJJEmerging drug profiles: Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765)Leuk Lymphoma201354112385239123425038
   PubMed Web of Science ®Google Scholar
• ChangBYFrancescoMDe RooijMFEgress of CD19(+) CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBlood2013122142412242423940282
   PubMed Web of Science ®Google Scholar
• RushworthSABowlesKMBarreraLNMurrayMYZaitsevaLMacEwanDJBTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κBCell Signal20132510611222975686
   PubMed Web of Science ®Google Scholar
• HermanSEMustafaRZGyamfiJAIbrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLBlood2014123213286329524659631
   PubMed Web of Science ®Google Scholar
• ZhengXDingNSongYFengLZhuJDifferent sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatmentCancer Cell Int20141413224693884
   PubMed Web of Science ®Google Scholar
• AdvaniRHBuggyJJSharmanJPBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesJ Clin Oncol2013311889423045577
   PubMed Web of Science ®Google Scholar
• Indications and Usage ImbruvicaFull Prescribing InformationPharmacyclics, Inc. Ref ID 33957882013
   Google Scholar
• MortonLMWangSSDevesaSSHartgePWeisenburgerDDLinetMSLymphoma incidence patterns by WHO subtype in the United States, 1992–2001Blood2006107126527616150940
   PubMed Web of Science ®Google Scholar
• GribbenJGHow I treat CLL up frontBlood2010115218719719850738
   PubMed Web of Science ®Google Scholar
• GribbenJGO’BrienSUpdate on therapy of chronic lymphocytic leukemiaJ Clin Oncol201129554455021220603
   PubMed Web of Science ®Google Scholar
• HarrisNLJaffeESSteinHA revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study GroupBlood199484136113928068936
   PubMed Web of Science ®Google Scholar
• ZhouYWangHFangWIncidence trends of mantle cell lymphoma in the United States between 1992 and 2004Cancer2008113479179818615506
   PubMed Web of Science ®Google Scholar
• RomagueraJEFayadLEFengLTen-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaBr J Haematol2010150199520020820528872
   PubMedGoogle Scholar
• ChenYWangMRomagueraJCurrent regimens and novel agents for mantle cell lymphomaBr J Haematol2014167131824974852
   PubMed Web of Science ®Google Scholar
• PackhamGStevensonFThe role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemiaSemin Cancer Biol201020639139920816790
   PubMed Web of Science ®Google Scholar
• de RooijMFKuilAGeestCRThe clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood20121192590259422279054
   PubMed Web of Science ®Google Scholar
• PonaderSChenSSBuggyJJThe Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood20121191182118922180443
   PubMed Web of Science ®Google Scholar
• ByrdJCFurmanRRCoutreSETargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaN Engl J Med20133691324223782158
   PubMed Web of Science ®Google Scholar
• O’BrienSFurmanRRCoutreSEIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialLancet Oncol2014151485824332241
   PubMed Web of Science ®Google Scholar
• FarooquiMZValdezJMartyrSIbrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialLancet Oncol201516216917625555420
   PubMed Web of Science ®Google Scholar
• ByrdJCBrownJRO’BrienSRESONATE InvestigatorsIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaN Engl J Med2014371321322324881631
   PubMed Web of Science ®Google Scholar
• BurgerJAKeatingMJWierdaWGSafety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyLancet Oncol201415101090109925150798
   PubMed Web of Science ®Google Scholar
• BrownJCBarrPMFlinnIIbrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study [Abstract 525]55th ASH Annual Meeting and Exposition2013
   Google Scholar
• JaglowskiSMJonesJAFlynnJMA phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseasesJ Clin Oncol201432suppl; abstr 70095s
   PubMedGoogle Scholar
• GoedeVFischerKBuschRObinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsN Engl J Med20143701101111024401022
   PubMed Web of Science ®Google Scholar
• BadouxXCKeatingMJWenSLenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemiaBlood2015118133489349921725050
   PubMedGoogle Scholar
• WangMLRuleSMartinPTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaN Engl J Med2013369650751623782157
   PubMed Web of Science ®Google Scholar
• WangMFayadLCabanillasFPhase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphomaCancer2008113102734274118973182
   PubMed Web of Science ®Google Scholar
• FisherRIBernsteinSHKahlBSMulticenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaJ Clin Oncol2006244867487417001068
   PubMed Web of Science ®Google Scholar
• CampoERuleSMantle cell lymphoma – evolving management strategiesBlood20151251
   Web of Science ®Google Scholar
• WangMLHagemeisterFWestinJRIbrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trialJ Clin Oncol2014
   Google Scholar
• O’BrienSMFurmanRRCoutreSEIndependent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p diseaseASCO Meet Abstr20143215_suppl7014
   Google Scholar
• YoungRMStaudtLMIbrutinib treatment of CLL: the cancer fights backCancer Cell2014261111325026208
   PubMed Web of Science ®Google Scholar
• WoyachJAFurmanRRLiuTMResistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinibN Engl J Med20143702286229424869598
   PubMed Web of Science ®Google Scholar
• European Hematology AssociationXIII Congress of the Italian Society of Experimental Hematology Rimini, Italy, October 15–17, 2014Haematology201499suppl 2S1S113
   Google Scholar
• WoyachJASmuckerKSmithLLProlonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyBlood20141231810181724415539
   PubMed Web of Science ®Google Scholar
• MaJLuPGuoACharacterization of ibrutinib-sensitive and -resistant mantle lymphoma cellsBr J Haematol2014166684986124957109
   PubMed Web of Science ®Google Scholar
• MedinaDJGoodellLGlodJGélinasCRabsonABStrairRKMesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathwaysHaematologica20129781255126322371181
   PubMed Web of Science ®Google Scholar
• ZhangLYangJQianJRole of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cellsBlood2012120183783379222968454
   PubMed Web of Science ®Google Scholar
• MedinaDJAbass-ShereefJWaltonKCobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cellsPLoS One201494e9104224722054
   PubMed Web of Science ®Google Scholar
• CheahCYChiharaDRomagueraJEPatients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomesAnn Oncol2015
   PubMedGoogle Scholar
• WoyachJARuppertASLozanskiGAssociation of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patientsASCO Meet Abstr20143215_suppl7010
   Google Scholar
• ByrdJCO’BrienSJamesDFIbrutinib in relapsed chronic lymphocytic leukemiaN Engl J Med20133691278127924066758
   PubMed Web of Science ®Google Scholar
• KleinBEKKleinRLeeKEGangnonREIncidence of age-related cataract over a 15-year interval. The Beaver Dam Eye StudyOphthalmology200811547748218171585
   PubMed Web of Science ®Google Scholar
• FarooquiMLozierJValdezJIbrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregationBlood2012120 Abstract1789
   Web of Science ®Google Scholar
• LevadeMDavidEGarciaCIbrutinib treatment affects collagen and von Willebrand factor-dependent platelet functionsBlood2015124263991399625305202
   PubMed Web of Science ®Google Scholar
• KamelSHortonLYsebaertLIbrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregationLeukemia201415
   Web of Science ®Google Scholar
• OuZZhangLNewberryKAbstract 2432: the Bruton’s tyrosine kinase inhibitor ibrutinib synergized with the proteasome inhibitor carfilzomib and overcame immunoproteasome-mediated carfilzomib resistance in mantle cell lymphomaCancer Res2013738 suppl2432
   Google Scholar
• WangMFayadLWagner-BartakNLenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialLancet Oncol201213771672322677155
   PubMed Web of Science ®Google Scholar
• GoyASinhaRWilliamsMESingle-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) studyJ Clin Oncol201331293688369524002500
   PubMed Web of Science ®Google Scholar
• EveHECareySRichardsonSJSingle-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differencesBr J Haematol2012159215416322881386
   PubMed Web of Science ®Google Scholar
• BurgerJABruton’s tyrosine kinase (BTK) inhibitors in clinical trialsCurr Hematol Malig Rep20149444924357428
   PubMed Web of Science ®Google Scholar